Aiming to change the game for millions of people around the world, Immutep (ASX: IMM; NASDAQ: IMMP) has introduced first-in-human trials of IMP761, a new LAG-3 agonist antibody designed to treat diseases autoimmune.
The start of this Phase I trial marks a vital milestone for Immutep and the broader scope of autoimmune disease research. By targeting the underlying cause of those debilitating conditions, rather than simply controlling symptoms, IMP761 represents a promising new treatment technique.
If successful, this treatment could offer hope to countless patients suffering from diseases such as rheumatoid arthritis, type 1 diabetes, and sclerosis, for which healing options have been lacking lately. The clinical network and patient advocacy teams will be watching the progress of this trial with interest.
Immutep’s resolution to start human trials is a testomony to the company’s confidence in the prospective of IMP761. Future protection and efficacy knowledge will be in figuring out the trail ahead for the drug.
About ImmutepImmutep is a clinical-stage biotechnology company focused on the advancement of novel LAG-3 immunotherapies for cancer and autoimmune diseases. The company is committed to patient outcomes through its cutting-edge technique targeting the immune system.
Receive updates directly to your inbox.
Terms of Use | Privacy Policy | Contact | Announce
Increases across the board of Deep Leads’ resources: quality, tonnage and target area ABx Group has reported a 30% increase in its mineral resource estimate (MRE) at Deep Leads’ rare ion adsorption clay (IAC) earth deposit in northern Tasmania. The accumulation in MRE comes from 36 tested outlets, representing a significant northward extension for the existing Deep Leads prospect.
Lake Resources (LKE. ASX) – LKE has signed two non-binding memorandums of understanding within 10 days. Ford Company (Ford) has signed a memorandum of understanding for about 25,000 t/year and last week, Hanwa, a Japanese commodity trader, signed a memorandum of understanding for up to 25,000 t/yr. Subject to execution, this is a feat as Ford and Hanwa are poised to collaborate on long-term strategic partnerships with LKE. Commercial negotiations are still ongoing but should, specifically if Ford and Hanwa inject new capital into LKE, remove additional risks in the financing of the task and thus ensure that LKE and Kachi are fully funded.
Two recent gravity studies have particularly exceeded expectations and revealed prospects for extension of the existing MRE at Throssell Lake, as well as a significant expansion opportunity at Yeo Lake. This reinforces the prospect of a multi-decade SOP Tier 1 production center around Lake Throssell.
Lately, TMG is completing paints in preparation for the PFS planned for early 2023, adding the start of drilling in the third quarter of 2022, evaporation testing and authorization activities. The effects of these systems will affect the PFS and any long-term resource improvements.
SOP benchmarks have increased to approximately $940/t due to recent geopolitical developments. The October 2021 scoping study assumed an SOP value of $550/t and contained a sensitivity study showing that every 10% increased value effects resulted in a +$144 million increase in task NPV of 364 million dollars. The approximately 70% increase compared to the scoping study implies an NPV of the allocation of approximately $1. 4 billion.
Despite the fall in oil and fuel prices, which fell 5. 4% and 19. 7% respectively in August, Calima managed to show an improvement in its main indicators.
WT Financial Group Limited (WTL) is a fast-growing diversified monetary company, founded in 2010 and indexed to the Australia Securities Exchange (ASX) in 2015. Their recommendations and product offerings are primarily provided through an organization of independent money advisors acting as legal advisors. Representatives. WTL in connection with its broker organization activities Wealth Today Pty Ltd (Wealth Today) and Sentry Group Pty Ltd (Sentry Group). He has approximately 275 advisers at over two hundred money advisory firms across Australia. It also operates a direct-to-consumer operation under its Spring Financial Group brand.
In May 2021, Corporate Connect analyst Marc Sinatra published a full study report on ASX-listed biotech Immutep Ltd (ASX: IMM). He was so inspired by IMM that Corporate Connect found it imperative to publish a follow-up report that valued the company, as the market did not see the great prospects of eftilagimod alfa (efti).
This monitoring report was published today. Using comparables, after adding a monetary rebate to its EV estimate and dividing by the total number of percentages issued, Corporate Connect now puts the fair price of a percentage of Immutep at A$2. 20.